Scholar Rock drops Novo manufacturing site from SMA drug application

Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug

Scholar Rock has shed Novo Nordisk’s troubled Cata | Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy…